Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698473 | 0.82 | MEN1 (0.53) | ALDH1A1SMN1; SMN2KMT2APOLBMEN1 | |
| SCHEMBL13698464 | 0.82 | ABCB1 (0.62) | ALDH1A1SMN1; SMN2KMT2APOLBMEN1 | |
| SCHEMBL12865073 | 0.78 | OPRM1 (0.52) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5460658 | 0.75 | GAA (0.62) | ALDH1A1TSHRSMN1; SMN2KMT2APOLB | |
| SCHEMBL14355430 | 0.74 | ALDH1A1 (0.54) | ALDH1A1TSHRUSP2 | |
| SCHEMBL13468008 | 0.74 | L3MBTL3 (0.59) | KMT2AMEN1 | |
| SCHEMBL13698468 | 0.74 | ALDH1A1 (0.57) | ALDH1A1TSHRSMN1; SMN2KMT2APOLB | |
| SCHEMBL13698472 | 0.73 | HSD17B10 (0.51) | ALDH1A1TSHRSMN1; SMN2KMT2APOLB | |
| SCHEMBL20756486 | 0.73 | HTT (0.55) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL14768684 | 0.72 | KDM4E (0.51) | ALDH1A1TSHRSMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | ALDH1A1 2270/4885TSHR 98/4885SMN1; SMN2 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.